98%
921
2 minutes
20
End-point free-energy methods as an indispensable component in virtual screening are commonly recognized as a tool with a certain level of screening power in pharmaceutical research. While a huge number of records could be found for end-point applications in protein-ligand, protein-protein, and protein-DNA complexes from academic and industrial reports, up to now, there is no large-scale benchmark in host-guest complexes supporting the screening power of end-point free-energy techniques. A good benchmark requires a data set of sufficient coverage of pharmaceutically relevant chemical space, a long-time sampling length supporting the trajectory approximation of the ensemble average, and a sufficient sample size of receptor-acceptor pairs to stabilize the performance statistics. In this work, selecting a popular family of macrocyclic hosts named cucurbiturils, we construct a large data set containing 154 host-guest pairs, perform extensive end-point sampling of several hundred nanosecond lengths for each system, and extract the free-energy estimates with a variety of end-point free-energy techniques, including the advanced three-trajectory dielectric-constant-variable regime proposed in our recent work. The best-performing end-point protocol employs GAFF2 for solute descriptions, the three-trajectory end-point sampling regime, and the MM/GBSA Hamiltonian in free-energy extraction, achieving a high ranking metrics of Kendall τ > 0.6, a Pearlman predictive index of ∼0.8, and a high scoring power of Pearson > 0.8. The current project as the first large-scale systematic benchmark of end-point methods in host-guest complexes in academic publications provides solid evidence of the applicability of end-point techniques and direct guidance of computational setups in practical host-guest systems.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acs.jcim.3c01356 | DOI Listing |
J Pharm Anal
August 2025
School of Pharmaceutical Sciences, Chongqing Key Laboratory of Natural Product Synthesis and Drug Research, Chongqing University, Chongqing, 401331, China.
Computational approaches, encompassing both physics-based and machine learning (ML) methodologies, have gained substantial traction in drug repurposing efforts targeting specific therapeutic entities. The human dopamine (DA) transporter (hDAT) is the primary therapeutic target of numerous psychiatric medications. However, traditional hDAT-targeting drugs, which interact with the primary binding site, encounter significant limitations, including addictive potential and stimulant effects.
View Article and Find Full Text PDFJ Chem Theory Comput
July 2025
Department of Pharmaceutical Sciences and Computational Chemical Genomics Screening Center, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, United States.
This work develops a hybrid machine learning/molecular mechanics (ML/MM) interface integrated into the AMBER molecular simulation package. The resulting platform is highly versatile, accommodating several advanced machine learning interatomic potential (MLIP) models while providing stable simulation capabilities and supporting high-performance computations. Building upon this robust foundation, we developed new computational protocols to enable pathway-based and end point-based free energy calculation methods utilizing ML/MM hybrid potential.
View Article and Find Full Text PDFNeural Comput
March 2025
Queen Square Institute of Neurology, University College London, Queen Square, London, WC1N 3BG, United Kingdom
Recent advances in theoretical biology suggest that key definitions of basal cognition and sentient behavior may arise as emergent properties of in vitro cell cultures and neuronal networks. Such neuronal networks reorganize activity to demonstrate structured behaviors when embodied in structured information landscapes. In this article, we characterize this kind of self-organization through the lens of the free energy principle, that is, as self-evidencing.
View Article and Find Full Text PDFPharmaceuticals (Basel)
February 2025
In Silico Toxicology Laboratory (inSiliTox), Department of Pharmacy, Health Sciences School, University of Brasilia, Brasilia 71910-900, Brazil.
The discovery and development of new pharmaceutical drugs is a costly, time-consuming, and highly manual process, with significant challenges in ensuring drug bioavailability at target sites. Computational techniques are highly employed in drug design, particularly to predict the pharmacokinetic properties of molecules. One major kinetic challenge in central nervous system drug development is the permeation through the blood-brain barrier (BBB).
View Article and Find Full Text PDFJ Chem Inf Model
February 2025
Zhejiang Laboratory, Hangzhou 311100, Zhejiang, China.
Deoxyribonucleic acid (DNA) serves as a repository of genetic information in cells and is a critical molecular target for various antibiotics and anticancer drugs. A profound understanding of small molecule interaction with DNA is crucial for the rational design of DNA-targeted therapies. While the molecular mechanics/Poisson-Boltzmann surface area (MM/PBSA) and molecular mechanics/generalized Born surface area (MM/GBSA) approaches have been well established for predicting protein-ligand binding, their application to DNA-ligand interactions has been less explored.
View Article and Find Full Text PDF